Ovarian Screening vs Control: Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00619 | 0.00541 | 0.00708 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.00513 | 0.00443 | 0.00594 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00106 | -0.0000662 | 0.00219 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.21 | 0.988 | 1.47 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.21 | 0.988 | 1.48 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Ovarian Screening than on Control | 945 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Ovarian Screening | Participants undergo blood sample collection for CA-125 analysis at baseline annually for 5 years. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. | 212 | 34,253 | OG001 | ClinicalTrials.gov |
| Group 2 | Control | Participants receive standard medical care. | 176 | 34,304 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers) | ClinicalTrials.gov |
| Description | Ovarian cancer diagnoses confirmed by medical record abstraction. | ClinicalTrials.gov |
| Time frame | Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years. | ClinicalTrials.gov |
| Population | Female participants, excluding females without ovaries at baseline, were analyzed. An intention-to-treat analysis was performed. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial) | ClinicalTrials.gov |
| NCT number | NCT01696994 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Ovarian Carcinoma, Ovarian Germ Cell Tumor | ClinicalTrials.gov |
| Interventions | Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging | ClinicalTrials.gov |
| Lead sponsor | National Cancer Institute (NCI) | ClinicalTrials.gov |
| Results first posted | 2014-12-12 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01696994?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.